CDKN2A and neoplasm: The treated tumor showed several CNVs in driver genes, including amplifications in MCL1, TERT, CCND1, AKT1, MYC, EGFR, and FGFR3; deletions in CDK1B, CDKN2A and CDKN2B; a PIK3CA hotspot mutation; and a high TMB.